Cardiothoracic & vascular anesthesia
Atrial natriuretic peptide in the prevention of acute renal dysfunction after heart transplantation—a randomized placebo‐controlled double‐blind trial
Authors' conclusion
The study failed to detect that ANP infusion attenuates renal dysfunction or decreases the incidence of AKI after heart transplantation.
Study context
- Population
- Heart transplantation patients
- Participants
- 70 patients
- Comparison
- Atrial natriuretic peptide (ANP) vs Placebo
- ANPn = 33
- Placebon = 37reference
- Primary endpoint
- Measured glomerular filtration rate (GFR) (measured GFR (mGFR)), by plasma clearance of a renal filtration marker
- Follow-up
- Day 4
Methodological detailsplacebo-controlled, double-blind
- Placebo-controlled
- Double-blind
Primary result
As reported in the abstract
mGFR
P = 0.705
Further findings
Need for dialysis during ongoing ANP infusion
P = 0.197
AKI incidence
P = 0.616
AKI stage 1
P = 0.420
AKI stage 2 or 3
P = 0.808
Original publication
Atrial natriuretic peptide in the prevention of acute renal dysfunction after heart transplantation—a randomized placebo‐controlled double‐blind trial. Acta Anaesthesiol Scand. Published 30 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →